Two cases of Lowe syndrome presenting as increased fetal nuchal translucency

Journal of Perinatal Medicine

Volumn 39, Issue 4, 2011, Pages 483-485

  Lin, Shin Yu ^a,b   Lee, Chien Nan ^b   Shih, Jin Chung ^b   Lin, Chia Hui ^b   Su, Yi Ning ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Lowe syndrome; nuchal translucency; OCRL gene

Indexed keywords

CLINICAL ASSESSMENT; DNA DETERMINATION; EARLY DIAGNOSIS; GENE MUTATION; GENETIC COUNSELING; HUMAN; KARYOTYPING; LETTER; LOWE SYNDROME; MOLECULAR MECHANICS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANT WOMAN; PRIMIGRAVIDA; PRIORITY JOURNAL;

ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; NUCHAL TRANSLUCENCY MEASUREMENT; OCULOCEREBRORENAL SYNDROME; PEDIGREE; PHOSPHORIC MONOESTER HYDROLASES; PREGNANCY;

EID: 79960231332     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2011.043     Document Type: Letter

References (15)

1. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109:217-27.
2. Addis M, Meloni C, Congiu R, Santaniello S, Emma F, Zuffardi O, et al. A novel interstitial deletion in Xq25, identified by array-CGH in a patient with Lowe syndrome. Eur J Med Genet. 2007;50:79-84. (Pubitemid 46097581)
3. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M. Increased nuchal translucency in euploid fetuses - what should we be telling the parents? Prenat Diagn. 2010;30: 93-102.
4. Cyvin KB, Weidemann J, Bathen J. Lowes syndrome. Acta Paediatr Scand. 1973;62:309-12.
5. Erdogan F, Ismailogullari S, Soyuer I, Ferahbas A, Poyrazoglu H. Different seizure types and skin lesions in oculocerebrorenal syndrome of Lowe. J Child Neurol. 2007;22:427-31. (Pubitemid 46909530)
6. Gaary EA, Rawnsley E, Marin-Padilla JM, Morse CL, Crow HC. In utero detection of fetal cataracts. J Ultrasound Med. 1993;12:234-6. (Pubitemid 23108189)
7. Loi M. Lowe syndrome. Orphanet J Rare Dis. 2006;1:16.
8. Michailidis GD, Economides DL. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol. 2001;17:102-5.
9. Miller RC, Wolf EJ, Gould M, Macri CJ, Charnas LR. Fetal oculocerebrorenal syndrome of Lowe associated with elevated maternal serum and amniotic fluid a-fetoprotein levels. Obstet Gynecol. 1994;84:77-80. (Pubitemid 24202962)
10. Schou KV, Kirchhoff M, Nygaard U, Jorgensen C, Sundberg K. Increased nuchal translucency with normal karyotype: a follow-up study of 100 cases supplemented with CGH and MLPA analyses. Ultrasound Obstet Gynecol. 2009;34:618-22.
11. Sethi SK, Lunardi J, Kabra M, Deka D, Bagga A. Antenatal diagnosis of Lowe syndrome. Clin Exp Nephrol. 2010;14: 296-7.
12. Silver DN, Lewis RA, Nussbaum RL. Mapping the Lowe oculocerebrorenal syndrome to Xq24-q26 by use of restriction fragment length polymorphisms. J Clin Invest. 1987;79:282-5. (Pubitemid 17232529)
13. Sonek J. First trimester ultrasonography in screening and detection of fetal anomalies. Am J Med Genet C Semin Med Genet. 2007;145:45-61. (Pubitemid 46427653)
14. Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 1998;11:391-400. (Pubitemid 28344740)
15. Souka AP, Krampl E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol. 2001;18:9-17. The authors stated that there are no conflicts of interest regarding the publication of this article.